ArticleACS omega2020
Green and Facile Synthesis and Antioxidant and Antibacterial Evaluation of Dietary Myricetin-Mediated Silver Nanoparticles.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring myricetin: A comprehensive review of its pharmacological potential, formulation strategies, and clinical outlook.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Chlorogenic Acid in Antitumor Therapy: Multi-Pathway Mechanisms, Nanocarrier-Mediated Smart Delivery, and Synergistic Combinatorial Strategies.International journal of nanomedicine · 2026Review
- Article
- Naringin and Naringenin Functionalized Silver Nanoparticles: Synthesis, Characterization and Biological Evaluation.Pharmaceutics · 2025Article
- Article
- Synthesis of AgJournal of functional biomaterials · 2025Article
- Unlocking the Pharmacological Potential of Myricetin Against Various Pathogenesis.International journal of molecular sciences · 2025Review
- Metal-Flavonoid Interactions-From Simple Complexes to Advanced Systems.Molecules (Basel, Switzerland) · 2024Review
- Article
- Value-Added Utilization of Citrus Peels in Improving Functional Properties and Probiotic Viability ofFoods (Basel, Switzerland) · 2022Article
- Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.Cancer cell international · 2022Review
- Modern Nanocarriers as a Factor in Increasing the Bioavailability and Pharmacological Activity of Flavonoids.Applied biochemistry and microbiology · 2022Article
- Bioinspired Nanomodification Strategies: Moving from Chemical-Based Agrosystems to Sustainable Agriculture.ACS nano · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myricetin (MY) is a dietary flavonoid which exhibits a wide spectrum of biological properties, viz., antibacterial, antioxidant, anticancer, and so forth. The lower solubility in aqueous medium and hence lesser bioavailability of MY limits the use of such dietary flavonoids in further in vivo research. To overcome bioavailability limitations, a number of drug-delivery systems are being investigated. Herein, MY-mediated silver nanoparticles (MY-AgNPs) were synthesized by a green approach to improve the therapeutic efficacy of MY. MY-AgNPs were characterized by ultraviolet-visible spectroscopy (UV-Vis), scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopy, and X-ray powder diffraction (XRD). The results showed that the dispersion of AgNPs had the maximum UV-vis absorption at about 410 nm. The synthesized nanoparticles were almost spherical. MY-AgNPs were further investigated against human pathogenic bacteria, and their antioxidant potential was also determined. The free radical scavenging rate was about 60-87%. MY-AgNPs had good antibacterial activity against
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.